Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Severe Hypereosinophilic Syndrome
NCT02836496Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2017
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Mepolizumab with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study at 32 weeks. Started Mar 2017; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT02836496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836496.